Evolent Health, Inc. (NYSE:EVH) Q1 2023 Earnings Call Transcript
Operator: Welcome to Evolent Health's Earnings Conference Call for the Quarter Ended March 31, 2023. As a reminder, this conference call is being recorded.
Evolent Health Inc. (EVH)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 3,803,500 | $123,423,575 | 2.94% | |
| 2. | OrbiMed Advisors Samuel Isaly | 2,895,632 | $93,963,258 | +3% | 1.84% |
| 3. | Engaged Capital Glenn W. Welling | 2,213,454 | $71,826,582 | -21% | 10.22% |
| 4. | Holocene Advisors Brandon Haley | 1,593,753 | $51,717,285 | +3% | 0.25% |
| 5. | Citadel Investment Group Ken Griffin | 1,435,480 | $46,581,326 | -45% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.73 | 14,749 | Officer, Director | 157,976 | 2019-12-04 | Filing | |
| $6.51 | 35,000 | Officer, Director | 623,655 | 2019-12-03 | Filing | |
| $7.04 | 7,200 | Director | 39,235 | 2019-08-15 | Filing | |
| $12.45 | 10,000 | Director | 38,212 | 2019-03-11 | Filing | |
| $7.03 | 15,000 | Director | 67,368 | 2019-08-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.74 | 49,026 | Director | 819,812 | 2023-06-01 | Filing | |
| $29.26 | 41,914 | Director | 868,838 | 2023-06-01 | Filing | |
| $29.75 | 9,969 | Director | 910,752 | 2023-06-01 | Filing | |
| $29.27 | 9,091 | Director | 920,721 | 2023-06-01 | Filing | |
| $36.29 | 110,000 | Director | 819,812 | 2023-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 14,641,699 | $461,373,133 | 0.04% | |
| 2. | 9,320,669 | $302,455,709 | 0% | |
| 3. | 6,928,258 | $224,821,971 | 0% | |
| 4. | 3,374,911 | $109,515,862 | 3.33% | |
| 5. | 3,342,586 | $108,466,915 | 0.03% |
News See All
Evolent Health, Inc. (NYSE:EVH) Q4 2022 Earnings Call Transcript
Operator: Welcome to Evolent Health's Earnings Conference Call for the Fourth Quarter and Year ended December 31, 2022. As a reminder, this conference call is being recorded.
5 High Growth Healthcare Stocks to Buy
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is one of the high growth healthcare companies that is working on treatments for neuropsychiatric and neurologic disorders.
Here's Why Evolent Health (EVH) Declined in Q4
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
Ray Dalio Stock Portfolio Q3 2022: Top 10 Small-Cap Stocks
In this article, we discuss the top 10 small-cap stocks from Ray Dalio’s Q3 2022 portfolio.
Top 10 Stock Picks of Joe Milano’s Greenhouse Funds
In this article, we examined Joe Milano’s portfolio management strategy and approach to investing in stocks. We also reviewed the top 10 stock picks of Joe Milano’s Greenhouse Funds.
Is Evolent Health (EVH) a Good Investment Choice in the Healthcare Sector?
Alger Capital, an investment management company, released its “Alger Small Cap Focus Fund” second quarter investor letter. A copy of the same can be downloaded here.
Were Expert Investors Right About Evolent Health Inc (EVH)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Have Never Been This Bullish On Evolent Health Inc (EVH)
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
5 Stocks to Invest in According to Kenneth Squire's 13D Management
In this article, we will discuss the 5 stocks to invest in according to Kenneth Squire's 13D Management.
Billionaire Hedge Funds
